Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications
Conditions
Interventions
Intervention1: Nil: Nil
Sponsors
INTRAMURAL RESEARCH FUND COMMITTEE JIPMER
Eligibility
Inclusion criteria
Inclusion criteria: A) For Cases 1. Patients started on metformin and glimepiride therapy who are on a stable drug regimen for atleast 6 months and reached the maximum tolerated dose and or or required other add-on antidiabetic drug and their Hb1Ac levels more than 7 percent. 2. Patients with type 2 diabetes mellitus of South Indian origin. South Indian origin is defined as patients with a history of three generations living in any of the southern States (Puducherry, Tamil Nadu, Kerala, Karnataka, Andhra Pradesh and Telangana) and speaking the respective local language as their mother tongue. 3. Both male and female gender. 4. Age 30 years and above. B) For Controls 1. Patients who are on a stable drug regimen of metformin, glimepiride for atleast 6 months and their Hb1Ac levels less than or equal to 7 percent. 2. Patients with type 2 diabetes mellitus of South Indian origin. South Indian origin is defined as patients with a history of three generations living in any of the southern States (Puducherry, Tamil Nadu, Kerala, Karnataka, Andhra Pradesh and Telangana) and speaking the respective local language as their mother tongue. 3. Both male and female gender. 4. Age 30 years and above.
Exclusion criteria
Exclusion criteria: A) For Cases 1. Poor adherence to combination therapy ( adherence rate of less than 90 percent will be considered as poor adherence). 2. Patients with a history of clinically proven renal or hepatic impairment. 3. Patients taking cationic medications like cimetidine, furosemide, nifedipine. 4. Pregnancy and lactation. 5. Patients who regularly consume alcohol [more than 4 standard drinks per day(1 standard drink equals to 10g of pure alcohol)]. 6. Patients who diagnosed to have type 1 diabetes, maturity-onset diabetes of the young (MODY), and secondary causes due to endocrinopathies, and chronic intake of steroidal drugs. B) For Controls 1. Patients with a history of clinically proven renal or hepatic impairment. 2. Patients taking cationic medications like cimetidine, furosemide, nifedipine. 3. Pregnancy and lactation. 4. Patients who regularly consume alcohol [more than 4 standard drinks per day (1 standard drink equals to 10g of pure alcohol) 5. Patients who are diagnosed to have type 1 diabetes, maturity-onset diabetes of the young (MODY) and secondary causes due to endocrinopathies, and chronic intake of steroidal drugs.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| To investigate the role of SLC22A1 (rs628031) & KCNJ11 (rs5219) polymorphisms in affecting dose requirements of metformin-glimepiride combination therapy among responders with type 2 diabetes mellitus.Timepoint: 4 weeks | — |
Primary
| Measure | Time frame |
|---|---|
| To study the association between variant genotypes of SLC22A1 (rs628031) & KCNJ11 (rs5219) and poor therapeutic response to metformin-glimepiride combined therapy in Type 2 Diabetes Mellitus patients of South Indian origin.Timepoint: 4 weeks | — |
Countries
India
Contacts
Public ContactDr R Kesavan
Jawaharlal Institute of Postgraduate Medical Education and Research
Outcome results
None listed